TY  - JOUR
AB  - Among the cell populations existing within a tumor, cancer stem cells are responsible for metastasis formation and chemotherapeutic resistance. In the present review, we focus on the transcription factor NF-κB, which is present in every cell type including cancer stem cells. NF-κB is involved in pro-tumor inflammation by its target gene interleukin 1 (IL1) and can be activated by a feed-forward loop in an IL1-dependent manner. Here, we summarize current strategies targeting NF-κB by chemicals and biologicals within an integrated cancer therapy. Specifically, we start with a tyrosine kinase inhibitor targeting epidermal growth factor (EGF)-receptor-mediated phosphorylation. Furthermore, we summarize current strategies of multiple myeloma treatment involving lenalidomide, bortezomib, and dexamethasone as potential NF-κB inhibitors. Finally, we discuss programmed death-ligand 1 (PD-L1) as an NF-κB target gene and its role in checkpoint therapy. We conclude, that NF-κB inhibition by specific inhibitors of IκB kinase was of no clinical use but inhibition of upstream and downstream targets with drugs or biologicals might be a fruitful way to treat cancer stem cells.
DA  - 2022
DO  - 10.3390/biomedicines10020261
KW  - cancer stem cells
KW  - NF-κB
KW  - EGF
KW  - PD-L1
KW  - lenalidomide
KW  - bortezomib
KW  - dexamethason
LA  - eng
IS  - 2
PY  - 2022
T2  - Biomedicines
TI  - Targeting NF-κB Signaling in Cancer Stem Cells: A Narrative Review
UR  - https://nbn-resolving.org/urn:nbn:de:0070-pub-29608107
Y2  - 2024-11-22T01:15:32
ER  -